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Background and Objectives. Hematopoietic stem cell
transplantation (HSCT) is associated with profound neu-
tropenia and significant morbidity and mortality. To eval-
uate the safety and efficacy of non-glycosylated recom-
binant human granulocyte colony-stimulating factor
(rHuG-CSF) in accelerating myeloid recovery and its influ-
ence on infections, supportive therapy, and transplant-
related mortality we carried out a randomized study in
pediatric patients receiving HSCT.
Design and Methods. Two hundred and twenty-one con-
secutive children, recipients of an allogeneic or autolo-
gous bone marrow (BM) or peripheral blood progenitor
cell (PBPC) transplant, were randomized to either receive
rHuG-CSF 10 µg/kg (n=110) or not (n=111).
Results. Myeloid engraftment was faster in the treated
arm (14 vs 20 days, p=0.0001). Neutrophil recovery was
accelerated both in the BM subgroups (allogeneic and
autologous, p=0.002) and in the PBPC group
(p=0.0005). All the other evaluated variables showed an
advantage in favor of rHuG-CSF treated patients that was
significant for platelet transfusion independence and
time to discharge (p=0.02 and p=0.04, respectively) only
in the BM subgroup.
Interpretation and Conclusions. We conclude that faster
neutrophil recovery in BM recipients receiving rHuG-CSF
led to clinical benefits, while, in the PBPC subgroup, it
did not translate into clinical advantages.
©2002, Ferrata Storti Foundation
Key words: rHu G-CSF, bone marrow transplantation,
children.
High dose chemo-radiotherapy followed byeither allogeneic or autologous hematopoi-etic stem cell transplantation (HSCT) is the
treatment of choice for an increasing number of
congenital and acquired diseases of childhood.1
One of the major drawbacks of this procedure is the
prolonged post-transplant period of profound neu-
tropenia, which may cause significant morbidity
and mortality.2
During the last decade hematopoietic growth
factors have been increasingly used after HSCT.
Although several phase II and phase III studies on
adult patients proved that recombinant human
granulocyte colony-stimulating factor (rHuG-CSF)
accelerates neutrophil recovery,3,4 the actual clini-
cal benefits of rHuG-CSF in children remain a con-
troversial point requiring controlled studies.4-8
It is well-known that children frequently recov-
er faster than adults after HSCT and suffer less
from life-threatening side effects, and this holds
true even for severe infections.9
Moreover, the kinetics of stem cell proliferation,
the hematopoietic reservoir, and the profile of the
effects of rHuG-CSF may be quite different from
those observed in adult patients. Indeed, in two
recent retrospective studies on pediatric patients
we obtained controversial results regarding the
clinical benefits of G-CSF following allogeneic bone
marrow transplant.10,11
We now report on a large randomized phase III
trial carried out to evaluate the safety and the effi-
cacy of non-glycosylated rHuG-CSF in accelerating
myeloid engraftment in children undergoing HSCT.
Moreover, we analyze whether acceleration of neu-
trophil recovery translates into secondary benefits
regarding infections, supportive therapy, hospital-
ization, and transplant-related mortality (TRM).
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Design and Methods
Selection of patients
Patients younger than 18 years and undergoing
allogeneic (HLA-matched sibling or unrelated
donor) or autologous [bone marrow (BM) or periph-
eral blood progenitor cell (PBPC)] transplant were
eligible for the study. Autologous BM transplant
was given mostly to children with hematologic
malignancies and autologous PBPC transplant was
given to children with solid tumors grafted since
January 1996. All allogeneic transplants used bone
marrow as the source of progenitor cells. Parents of
all children gave written informed consent and
understood the experimental nature of the proto-
col. The study was approved by the Institutional
Review Board at each of the participating Institu-
tions. Patients were centrally randomized by a com-
puter generated random list, stratified according to
type of transplant (allogeneic: sibling or unrelated
donor; autologous: BM or PBPC), and disease risk,
as shown in Table 1. 
From January 1995 to June 1998, 221 consecu-
tive patients aged 0.16 to 17.9 years (median 6.6
years) were enrolled in 9 Italian centers affiliated to
the Italian Association of Pediatric Hematology and
Oncology (AIEOP). The characteristics of the
patients, divided according to treatment group, are
reported in Table 1.
rHuG-CSF treatment
Children randomized into the treament arm
received rHuG-CSF in 100 mL saline as a 2-hour
intravenous infusion daily at a dose of 10 µg/kg
body weight. Treatment started on day +5 and last-
ed for 25 consecutive days, or until the absolute
neutrophil count (ANC) reached 0.5×109/L for 3
consecutive days, whichever occurred first.
Clinical monitoring
Children were kept in positive pressure rooms
equipped with HEPA filters and were together with
one of their parents. Blood cell counts with differ-
ential and blood chemistries were monitored daily.
Children were transfused on a routine basis when
the hematocrit was below 30%, and received
platelet transfusions for counts below 20×109/L or
in the presence of hemorrhage. Total parenteral
nutrition (TPN) was given to maintain calorie intake
over 50% of the daily requirement. Blood compo-
nents were irradiated and filtered to reduce cont-
aminating leukocytes. Febrile episodes were classi-
fied according to the European Organization for
Research and Treatment of Cancer criteria.12 When
patients developed fever or any sign of infection
they were treated with broad-spectrum antibiotics
according to the Center’s policy. Graft-versus-host
disease (GvHD) prophylaxis included cyclosporin A
(CSA) in children receiving HSCT from a sibling
donor, CSA associated with short-term methotrex-
ate (MTX) and antilymphocyte globulin (ALG) in
children transplanted from an unrelated donor (UD).
The severity of acute GvHD was scored weekly using
standard criteria.13 Pretransplant preparative regi-
mens were assigned according to institutional pro-
tocols, on the basis of the underlying disease and
phase, as well as on the recipient’s age. Patients
were discharged when they were afebrile and off
parenteral antibiotics and antimycotics for at least
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Table 1. Characteristics of patients divided according to
treatment group.
TG CG p
(n=110) (n=111)
Type of transplant ns#
Autologous
BM 34 32
PBPC 33 31
Allogeneic
Sibling 23 30
Unrelated 20 18
Age at transplant (yrs) ns$
median 6.7 6.7
range 1.2–17,9 0.16–17,9
Diagnosis-transplant interval ns$
(months)
median 10 9.8
range 1-119 1-135
Gender ns#
Male/Female 68/42 65/46
Primary diagnosis ns#
Standard risk 110 99
AL 2nd CR 34 43
CML 1st CP 5 4
Non-Hodgkin’s lymphoma 1st CR 6 7
SAA 1 1
RA − 1
Congenital diseases 5 4
Solid tumors 49 39
Advanced risk 10 12
AL 3rd CR 7 6
CML >1st CR 1 1
Non-Hodgkin’s lymphoma >1st CR 1 5
SAA >3 months 1 1
Conditioning regimen ns#
TBI + chemotherapy 43 52
Chemotherapy alone 64 58
Not known 5 −
Mononuclear cells infused (108/kg) ns$
Median 3.3 3
Range 0.3–20.9 0.03– 61
Abbreviations: TG, treated group; CG, control group; #two-tailed Fisher’s exact
test; BM, bone marrow; PBPC, peripheral blood progenitor cell; $Wilcoxon’s rank
sum test and t-test; AL, acute leukemia; CR, complete remission; CML, chronic
myelogenous leukemia; CP, chronic phase; SAA, severe aplastic anemia;
RA, refractory anemia; TBI, total body irradiation.
72 hours, their oral intake provided more than 60%
of the daily calorie requirement, and in the absence
of diarrhea.
Statistical analysis
All data were stored in a central data base
(AIEOP–BMT Registry), organized at the AIEOP
Operation Office.14 Demographic and clinical char-
acteristics of the two groups of patients were com-
pared using the two-tailed Fisher’s exact test for
categorical variables (gender, disease, type of trans-
plant, and conditioning regimens), the Wilcoxon’s
rank sum test and the t-test for continuous vari-
ables (age, diagnosis - HSCT interval, and marrow
cell dose).15 The primary end-point of this study was
to evaluate neutrophil recovery, defined as the first
of three consecutive days with an ANC of at least
0.5×109/L. Other variables evaluated included time
to the last platelet transfusion, time to the last red
blood cell transfusion, number of febrile days, days
on intravenous antibiotic therapy, duration of TPN,
duration of hospitalization after infusion, incidence
of  grade ≥ II acute GvHD, TRM and event-free sur-
vival (EFS), and incidence of relapse.
In order to understand the role of rHuG-CSF bet-
ter, all variables were separately analyzed accord-
ing to transplant type. Subsequently, we carried out
the same statistical analysis gathering the three
bone marrow subgroups (autologous and allogene-
ic-familial and unrelated), but excluding PBPC. The
effects of treatment in terms of neutrophil recov-
ery, TRM, EFS and relapse rate (RR) were examined
in unvariate analysis according to the Kaplan-Meier
method.16 The generalized Wilcoxon test17 and the
log-rank test were applied for comparing the out-
come of the randomized groups. A Cox regression
model was applied to estimate treatment effect
adjusting for covariates.18 All analyses were per-
formed according to the intention-to-treat princi-
ple. The study had an 80% power to detect a 20%
difference in neutrophil recovery, considering a
baseline 15-day neutrophil recovery probability for
the control group of 0.75 and α = 0.05 (two-sided),
resulting from a minimum sample size of 53
patients per arm. Since 60 autologous and 50 allo-
geneic BMT were expected per year, two years’
accrual made it possible to evaluate the primary
end point both in allogeneic and autologous sub-
group analyses. The SAS package (SAS Institute,
Cary, NC, USA) was used for analysis of the data.
Results
From January 1995 to June 1998 221 patients
were randomly assigned to the group treated with
rHuG-CSF (n=110) or to the control group (n=111).
Treated children and controls were comparable in
terms of clinical characteristics (Table 1). rHuG-CSF
was well tolerated, no side effects or hepatic or
renal abnormalities potentially related to the drug
were reported, and no children in the treated arm
required treatment discontinuation, and no chil-
dren in the control group received rHuG-CSF.
Blood cell recovery and transfusion
Two hundred and sixteen out of 221 (98%)
patients reached myeloid engraftment at a mean of
17 days (range: 8-63; 95% confidence interval-CI:
16-18). The five patients who did not (3 undergo-
ing autologous BMT, 1 allogeneic sibling and 1 UD
BMT) died of infections on days 8-53 (median 31
days).
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Figure 1. A. Granulocyte engraftment by randomization: all
patients. B. Granulocyte engraftment by randomization;
autologous and allogeneic bone marrow transplantation.
C. Granulocyte engraftment by randomization: autologous
PBPC transplant.
A
B
C
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Three were in the treated group and two were in
the control group. The mean time to ANC >0.5×109/L
was significantly shorter in patients treated with
rHuG-CSF than in the control group: 14 (95% CI:
13-15) vs 20 (95% CI: 18-22) days, respectively;
p=0.0001 (Figure 1A). Subgroup analysis confirmed
the faster kinetics of neutrophil recovery in autolo-
gous PBPC transplants (p=0.0005), and in BMT (allo-
geneic and autologous) (p=0.002) recipients (Table
2 and Figures 1B and 1C).
The mean day of the last red cell transfusion was
comparable in the two randomization arms. The
mean day of the last platelet transfusion was 36
(95% CI: 27-45) for rHuG-CSF treated patients
undergoing BMT (autologous and allogeneic) and
59 (95% CI: 41-77) days for the controls (p=0.02),
whereas there was no difference in favor of the
rHuG-CSF group in patients undergoing PBPC trans-
plant (Table 2).
Supportive care
A trend towards shorter antibiotic treatment,
shorter TPN duration, and fewer days of fever was
observed in the rHuG-CSF-treated patients. In some
subgroups of patients a significant difference in
favor of the treatment group was observed (Table 3).
Hospitalization
The duration of hospitalization after BMT (autol-
ogous and allogeneic) was shorter (p<0.04) in rHuG-
CSF treated patients (37 days; 95% CI: 31-43) than
in controls (46 days; 95% CI: 39-53), whereas there
was no difference between the two arms in patients
undergoing autologous PBPC transplant (Table 3). 
Other management issues
In the allogeneic BMT setting no differences were
observed in the incidence of grade II-IV acute GvHD
(25/43 and 27/48 patients at risk in the treated and
control groups, respectively) and of extensive
chronic GvHD (8/11 and 9/17, respectively). In all
subgroups the actuarial probabilities of EFS, relapse,
and TRM at 100 days and at 48 months after HSCT
were comparable in treated patients and controls.
In patients with malignancies, the relapse rate did
not differ significantly in the two groups (Table 4).
Discussion
Several clinical studies have addressed the issue
of the benefits of using hematopoietic growth fac-
tors following HSCT.3-8 Most of these studies were
performed on adults, while few trials were per-
formed on children. The 1998 recommendations of
a European committee on the use of colony-stimu-
lating factors (CSF) in children19 stated that rHuG-
CSF should be used routinely as an adjuvant in
autologous, but not in allogeneic BMT, or in autol-
ogous PBPC transplants and suggested that
prospective studies were required to draw evidence-
based guidelines. In vitro studies on T-cells derived
from allogeneic BMT recipients showed decreased
ability to produce CSFs, which may account for an
increased susceptibility to infections.20 A large
placebo-controlled phase III trial evaluated the role
of glycosylated rHuG-CSF in a group of 315 patients,
including 46 children, receiving either autologous
or allogeneic BMT. rHuG-CSF therapy in all patients,
including children, was associated with a faster ANC
recovery, fewer febrile-neutropenic days, fewer days
of TPN, fewer microbiologically documented infec-
tions, and a shorter period of hospitalization.4 To
our knowledge, our study is the largest phase III tri-
al reported to date analyzing the use of hematopoi-
etic CSF in children. Our study demonstrated the
reproducibility of results reported in adults on a
large number of transplanted patients below 18
years of age. Ninety-eight percent of the patients
successfully reached myeloid engraftment. The drug
Table 2. Hematologic parameters in the two groups, expressed as means (95% confidence interval).
Type of transplant Auto PBPC Auto BMT Allo Sib. BMT Allo UD BMT Auto + Allo BMT
TG CG p# TG CG p# TG CG p# TG CG p# TG CG p#
N. of patients 33 31 34 32 23 30 20 18 77 80
Days to ANC* 11 14 O.0005 18 28 0.002 11 18 ns 13 19 0.004 15 22 0.002
>0.5×109/L (10-12) (12-16) (14-21) (22-32) (10-12) (12-24) (12-14) (15-23) (13-17) (19-25
Time to last RBC* 21 53 ns 38 55 ns 28 61 ns 64 64 ns 52 60 ns
transfusion (days) (10-31) (5-100) (23-53) (28-82) (13-43) (27-95) (31-97) (41-87) (33-71) (43-77)
Time to last PLT* 27 31 ns 39 63 ns 21 58 ns 33 57 ns 36 59 0.02
transfusion (days) (11-43) (7-56) (25-54) (34-91) (13-29) (23-93) (22-44) (34-80) (27-45) (41-77)
Abbreviations: Auto: autologous; PBPC: peripheral blood progenitor cell transplant; pts: patients; BMT: bone marrow transplant; Allo: allogeneic; Sib: sibling;
UD: unrelated donor; TG: treatment group; CG: control group; #t-test; ANC: absolute neutrophil count; RBC: red blood cell; PLT: platelet; ns, not significant.
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was very well tolerated by the children, and no
adverse effects were reported. Compared to the con-
trol group, rHuG-CSF accelerated myeloid engraft-
ment after autologous PBPC transplant as well as
after autologous and allogeneic BMT. The difference
reached a statistical significance in all subgroups
except that of patients receiving an allogeneic sib-
ling HSCT, probably due to the low number of
patients in this group. In addition to the effect on
hematopoietic recovery, this study attempted to
prospectively determine the effect of rHuG-CSF
treatment on some clinical parameters. The results
demonstrated that the faster myeloid engraftment
in pediatric patients undergoing autologous and
allogeneic BMT resulted in a somewhat reduced
post-transplant morbidity. This led to a decrease in
the duration of hospitalization which was signifi-
cant in the overall allogeneic + autologous popula-
tion and in the autologous BMT subgroup. The dif-
ference did not reach a statistical difference in allo-
geneic BMT, probably due to the low number of
patients. A trend towards shorter antibiotic treat-
ment, shorter TPN, and fewer days of fever was
observed in rHuG-CSF-treated patients. This differ-
ence was not statistically significant when com-
pared to controls, possibly due to the limited sam-
ple size. In keeping with the results reported by
Kawano et al.8 rHuG-CSF appeared to provide lim-
ited benefits when used after autologous PBPC
transplant in a pediatric population. Two factors
may explain this difference from results of adult
studies: the potentially higher cell dose infused in
lower weight patients, and the possibly more effi-
cient hematopoiesis in children than in adults.8 Fur-
thermore, it must be noted that, as previously
reported,21 all the measured variables showed low-
er toxicity and faster recovery in patients undergo-
ing autologous PBPC transplant than in patients
undergoing autologous BMT, regardless of the use of
rHuG-CSF. As shown by Kawano et al.,8 further ben-
efits induced by growth factor administration can-
not be achieved. The clinical benefit of the reinfu-
sion of large numbers of earlier engrafting commit-
ted progenitor cells22 led most study groups to shift
from the use of BM to PBPC, especially in the set-
ting of solid tumors. Recently, some investigators
have hypothesized that the administration of
growth factors after transplantation may be detri-
mental to platelet recovery.8,23,24 In addition, con-
flicting data have been reported on the impact of
growth factors following allogeneic BMT on the
incidence of acute GvHD.23,25,26 The results of our
Table 3. Other clinical variables evaluated in the two groups, expressed as means (95% confidence interval).
Type of transplant Auto PBPC Auto BMT Allo Sib. BMT Allo UD BMT Auto + Allo BMT
TG CG p# TG CG p# TG CG p# TG CG p# TG CG p#
N. of patients 33 31 34 32 23 30 20 18 77 80
N. of  febrile days* 5 6 ns 9 10 ns 9 9 ns 10 12 0.04 9 11 ns
(4-6) (4-7) (4-11) (6-13) (5-13) (7-11) (7-13) (9-15) (7-11) (9-13)
Days on antibiotic therapy 13 14 ns 18 19 ns 15 22 0.03 20 23 ns 19 22 ns
(10-16) (12-16) (15-21) (16-23) (12-18) (18-26) (17-23) (20-26) (17-21) (20-24)
Duration of TPN (days) 17 16 ns 20 27 0.03 21 30 0.03 31 32 ns 26 30 ns
(14-20) (14-18) (17-24) (22-32) (17-25) (25-35) (24-38) (27-37) (22-30) (26-34)
Duration of 22 22 ns 27 34 0.02 32 46 ns 46 54 ns 37 46 0.04
hospitalization (days) (18-25) (18-26) (24-31) (29-39) (25-29) (12-180) (37-55) (55-64) (31-43) (39-53)
Abbreviations: Auto: autologous; PBPC: peripheral blood progenitor cell transplant; pts: patients; BMT: bone marrow transplant; Allo: allogeneic; Sib: sibling; UD: unrelated
donor; TG: treatment group; CG: control group; #: t-test; MDI: microbiologically documented infections; TPN: total parenteral nutrition; ns, not significant.
Table 4. Clinical outcome.
Auto PBPC pts Auto + Allo BMT pts
TG CG p# TG CG p#
%(SE) %(SE) %(SE) %(SE)
TRM at 100 days 0 6.7 ns 10.5 8.8 ns
(4.6) (3.5) (3.2)
TRM at 48 months 3.6 14.5 ns 21.0 18.7 ns
(3.5) (7.0) (4.9) (4.6)
RR at 48 months 61.5 67.1 ns 42.1 30.3 ns
(9.0) (9.2) (6.1) (5.6)
EFS at 48 months 36.8 26.7 ns 44.1 55.5 ns
(8.1) (5.7) (5.6)
Abbreviations: Auto, autologous, PBPC, peripheral blood progenitor cells;
pts, patients; Allo, allogeneic; BMT, bone marrow transplant; TG, treated group;
CG, control group; #log-rank test; SE, standard error; TRM, transplant-related
mortality; RR, relapse rate; EFS, event-free survival; ns, not significant.
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study showed that the use of rHuG-CSF was asso-
ciated with a favorable effect on the time to inde-
pendence from platelet transfusion in children
undergoing allogeneic or autologous BMT. This was
not observable in children undergoing PBPC trans-
plant, in keeping with the results reported by
Kawano et al.8 In our study, time to last platelet
transfusion was four days later in the PBPC sub-
group receiving rHuG-CSF, possibly influencing
duration of hospitalization and costs. The reasons
for these different results need to be clarified and
further investigation on this point is required. There
was no evidence in the present study that the rHuG-
CSF regimen had any effect on the incidence or
severity of GvHD, or on the incidence of relapse.
Schriber et al.27 observed a higher than expected
early mortality in patients receiving rHuG-CSF after
BMT from a matched unrelated donor. In our study
TRM at 100 days and survival did not differ between
the two randomization arms, regardless of the type
of stem cells or donor used.
In our study rHuG-CSF administration was start-
ed on day +5 in order to avoid the possible nega-
tive influence of early administration and to save
costs.29 Recently, it has been shown that postpon-
ing treatment with rHuG-CSF from day 1 to day 5
or even later after HSCT had no significant effect on
hematopoietic engraftment and furthermore,
delaying rHuG-CSF treatment was associated with
a significant saving in costs.30,31,32 Moreover, it has
been reported that early administration of rHuG-
CSF was associated with a higher frequency of
veno-occlusive disease27 and with a significant drop
in plasma antithrombin levels.29 In our study we
administered rHuG-CSF at a daily dose of 10 µg/kg
body weight, although we cannot exclude that a
different dose may be equally effective.19,31,33
In conclusion, on the basis of our results the
administration of rHuG-CSF in children at a dose of
10 µg/kg/day from day 5 following allogeneic and
autologous BMT was safe and effective because it
accelerated myeloid engraftment and significantly
decreased the period spent in hospital. The observed
trend in favor of the treated group, in terms of
antibiotic and TPN requirements, was probably
responsible for the earlier discharge. On the other
hand we confirmed that the use of rHuG-CSF pro-
vided marginal clinical benefits to children under-
going autologous PBPC transplantation.
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What is already known on this topic
Recombinant human granulocyte colony-stimulating fac-
tor (rHuG-CSF) accelerates neutrophil recovery after HSCT
in adults, but the actual clinical benefits of rHuG-CSF in
children remain controversial.
What this study adds
This prospective randomized phase III trial demonstrates
that although faster neutrophil recovery was observed in
both BM and PBPC rHuG-CSF treated groups, significant
clinical benefits were only observed in BM recipients.
Potential implications for clinical practice
As in adults, rHuG-CSF administration in children at a
dose of 10 µg/kg/day from day 5 of SCT is safe and
effective, leading to clinical benefits at least in patients
submitted to allogeneic or autologous BMT. On the other
hand, other trials are required to clarify the clinical use-
fulness of the systematic use of rHuG-CSF in children
undergoing autologous PBPC transplantation.
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